BPC-157 and TB-500 are investigational peptides, not FDA-approved drugs. Reported side effects may include injection-site irritation, fatigue, nausea, headache, dizziness, and appetite, mood, sleep, or energy changes, but reliable human safety data are limited. The biggest concern is uncertainty: dose, purity, sterility, long-term effects, and cancer-related risks are not well established in people.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →What are BPC-157 and TB-500?
BPC-157 and TB-500 are synthetic peptides discussed online for tissue repair and injury recovery. In plain terms, they are short amino-acid chains studied for signals involved in wound healing, inflammation, blood-vessel growth, and cell movement, but that does not mean they have proven benefits in humans.
BPC-157: a synthetic 15-amino-acid peptide
BPC-157 stands for Body Protection Compound-157. It is also called Bepecin, PL 14736, PL10, or a synthetic pentadecapeptide, meaning a synthetic peptide made of 15 amino acids. Reviews describe BPC-157 as a stable fragment related to a body protection compound first studied in gastric tissue, with research focused on tissue protection, wound healing, inflammatory pathways, nitric oxide signaling, and angiogenesis, which means new blood-vessel growth 1.
The important limit: most BPC-157 evidence is animal, cell, or early translational research. A sports-medicine review found growing interest but limited controlled human data for safety or effectiveness in orthopedic recovery 2.
TB-500: a synthetic fragment related to thymosin beta-4
TB-500 is commonly described as a synthetic peptide fragment related to thymosin beta-4, a naturally occurring protein involved in actin regulation. Actin is a structural protein cells use to move, change shape, and help rebuild tissue. Thymosin beta-4 has been studied in wound repair, cell migration, inflammation modulation, and angiogenesis, but TB-500 itself has far less direct human evidence 3, 4.
Why people combine them for injury recovery
People often discuss a BPC-157 and TB-500 “stack” because the proposed mechanisms sound complementary: BPC-157 is framed around tissue protection and nitric oxide pathways, while TB-500 is framed around actin regulation and cell migration. That rationale is biologically plausible, but additive benefit has not been proven in controlled human trials, and side effects may also be additive or unpredictable 1, 3.
What are the quick facts on FDA status, evidence, and sports rules?
BPC-157 and TB-500 sit in a different evidence category than FDA-approved medicines. The most useful way to think about them is: interesting biology, limited human proof, meaningful quality concerns, and special rules for competitive athletes.
| Question | BPC-157 | TB-500 |
|---|---|---|
| FDA approval status | Not FDA approved as a drug for injury recovery, pain, gut healing, or longevity | Not FDA approved as a drug for injury recovery, muscle repair, or longevity |
| Human evidence level | Limited; most proposed benefits are based on animal, cell, and early clinical discussion | Very limited direct human evidence; much of the biology is inferred from thymosin beta-4 research |
| Commonly reported side effects | Injection-site irritation, fatigue, headache, dizziness, nausea, appetite or mood changes | Injection-site irritation, fatigue, headache, dizziness, nausea, appetite or mood changes |
| Main unknowns | Dose, long-term safety, cancer-related effects, immune reactions, purity, sterility, and strength | Dose, long-term safety, cancer-related effects, immune reactions, purity, sterility, and strength |
| Sports considerations | Competitive athletes should check anti-doping rules before use | Competitive athletes should check anti-doping rules before use |
The World Anti-Doping Agency prohibited list includes many growth factors, growth-factor modulators, and related substances; athletes should confirm current rules with their sport’s anti-doping authority before using any recovery peptide 8.
What side effects have people reported with BPC-157 and TB-500?
Reported side effects are mostly nonspecific, and true rates are not known because these peptides have not been tested like FDA-approved drugs. Side-effect lists from online use cannot tell us how often symptoms happen, which symptoms are caused by the peptide, or whether product quality played a role.
Injection-site redness, pain, swelling, or irritation
For injectable peptides, local injection-site reactions are among the most plausible short-term issues. Redness, pain, swelling, itching, bruising, or irritation can come from the peptide, the solution, the injection technique, or contamination risk 5.
Fatigue, headache, dizziness, or lightheadedness
Fatigue, headache, dizziness, and lightheadedness are often discussed in wellness settings for BPC-157 and TB-500, but controlled studies do not define reliable rates. Because these symptoms can also reflect dehydration, blood-pressure changes, infection, medication interactions, or other illness, they should not be brushed off as “normal peptide effects” 1, 3.
Nausea, digestive symptoms, or appetite changes
Nausea, digestive discomfort, and appetite changes are also reported. BPC-157 has been studied in gastrointestinal injury models, but animal gut findings do not prove safety or benefit for human digestive symptoms 1, 2.
Mood, sleep, or energy changes
Some people describe mood, sleep, or energy changes while using recovery peptides. These are hard to interpret because sleep, pain, training load, other medications, and expectation effects can all change how a person feels.
Why online reports cannot tell us true side-effect rates
Online reports are not the same as a controlled trial. They often miss product testing, dose confirmation, medical history, other medications, and follow-up. That is why the honest answer for BPC-157 and TB-500 side-effect rates is: we do not know yet.
What are the bigger safety concerns beyond short-term side effects?
The bigger safety issue is not just how someone feels the next day. It is whether the product is what the label says it is, whether it is sterile for injection, whether impurities are present, and whether long-term human effects are being missed.
Uncertain purity and strength in non-approved products
FDA has warned that some bulk drug substances used in compounding may present significant safety risks, including limited safety information and quality concerns 5. For peptides sold outside a licensed prescription pathway, identity, strength, purity, and contamination may be uncertain.
Sterility risks with injectable peptides
Sterility matters because an injected product bypasses the skin barrier. If a peptide vial, diluent, needle, or mixing process is contaminated, infection can occur. This is why the safety axis we emphasize at Chia is licensed care: a licensed clinician and a state-licensed 503A compounding pharmacy versus no-prescription “research chemical” vendors.
Immune reactions, aggregates, and peptide-related impurities
Peptides can raise immune-system questions, including immunogenicity, peptide aggregates, and peptide-related impurities. FDA has named these types of concerns when discussing certain bulk substances and compounded products 5.
Unknown long-term safety in humans
Long-term safety is unknown because neither BPC-157 nor TB-500 has the kind of large, long, controlled human safety database expected for FDA-approved drugs. That matters most for people with cancer history, autoimmune disease, cardiovascular disease, pregnancy, fertility goals, or complex medication lists.
Why combining two investigational peptides adds uncertainty
Using two investigational peptides together may increase uncertainty. Even if each peptide looks tolerable alone in limited reports, that does not prove the combination is safer, more effective, or predictable.
Can BPC-157 or TB-500 affect the heart or blood vessels?
Blood-vessel biology is central to why these peptides get attention. BPC-157 has been discussed in relation to nitric oxide signaling and angiogenesis, while thymosin beta-4 biology includes cell migration and blood-vessel formation pathways, but mechanisms are not proof of cardiovascular benefit or safety in people 1, 4.
What nitric oxide and angiogenesis pathways mean
Nitric oxide is a signaling molecule involved in blood-vessel tone. Angiogenesis means new blood-vessel growth, often discussed with vascular endothelial growth factor, or VEGF. These pathways matter in healing, but they also matter in other biology, including tumor growth and abnormal vessel formation 6.
Why blood-vessel effects are not the same as proven cardiovascular benefit
A peptide affecting nitric oxide or angiogenesis in a lab model does not prove it protects the human heart, improves circulation, or is safe for someone with heart disease. People with chest pain, fainting, palpitations, shortness of breath, or sudden weakness need urgent medical care, not peptide troubleshooting.
Is there a cancer concern with BPC-157 or TB-500?
Cancer questions come up because healing, angiogenesis, VEGF signaling, inflammation, and tissue remodeling overlap with cancer biology. That does not prove BPC-157 or TB-500 causes cancer, but it also does not prove they are safe for people with current or prior cancer.
Why angiogenesis is discussed in healing and cancer biology
Angiogenesis helps bring blood supply to healing tissue. Cancer can also use blood-vessel growth to support tumor expansion, which is why pro-angiogenic signals are handled carefully in cancer research 6.
What the current evidence can and cannot prove
Current evidence cannot prove that BPC-157 or TB-500 causes cancer in humans. It also cannot prove that they are safe in people with active cancer, prior cancer, high-risk lesions, or incomplete cancer screening. A 2025 review of BPC-157 and TB-500 highlighted the need for stronger clinical trials and safety monitoring, including cancer-related caution 3.
Why people with current or prior cancer should be especially cautious
People with current cancer, prior cancer, unexplained weight loss, abnormal bleeding, a new lump, or overdue cancer screening should talk with an oncology-informed clinician before considering any investigational recovery peptide. This is a risk-framing point, not a claim that the peptides are proven to cause cancer.
What happens when you take BPC-157 and TB-500 together?
Taking them together is often called stacking. The proposed logic is that BPC-157 may support tissue-protection pathways while TB-500 may support actin-related cell migration, but combination-specific human trials have not proven better recovery or defined safety.
- Proposed rationale: tissue protection plus cell migration sounds complementary, especially for tendon, ligament, muscle, or wound-repair discussions.
- Evidence limit: animal and cell findings do not prove that a stack improves human injury recovery.
- Safety limit: side effects, immune reactions, drug interactions, and product-quality risks may be additive or unpredictable.
- Practical point: if a recovery goal is real, a clinician should first clarify the diagnosis and compare options with stronger human evidence.
Can you take BPC-157 and TB-500 every day?
There is no FDA-approved daily dosing schedule for BPC-157 or TB-500. Online “cycle” protocols are not the same as medical guidance, and we do not provide dosing instructions for investigational peptides.
Daily use raises the same questions as any repeated exposure: What is the diagnosis? What is the target outcome? How is safety monitored? What happens if symptoms change? What other medications or conditions could interact? Without controlled human dosing studies, daily use remains an uncertainty, not a standard plan.
How do BPC-157 and TB-500 compare?
BPC-157 vs TB-500 is less about “which is safer” and more about different proposed mechanisms with the same core evidence problem. Both are investigational, both lack FDA-approved indications, and both have limited human safety data.
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Other names | Body Protection Compound-157, Bepecin, PL 14736, PL10, synthetic pentadecapeptide | Synthetic fragment related to thymosin beta-4 |
| Main proposed mechanism | Tissue protection, inflammatory modulation, nitric oxide signaling, angiogenesis | Actin regulation, cell migration, wound repair, inflammation, angiogenesis |
| Evidence base | Mostly animal, cell, and early translational evidence; limited controlled human data | Mostly thymosin beta-4 biology, animal, and lab evidence; limited direct TB-500 human data |
| Side-effect certainty | Reported symptoms exist, but true rates are not known | Reported symptoms exist, but true rates are not known |
| Regulatory status | Not FDA approved; PCAC recommended 503A Bulks List inclusion, FDA final determination pending | Not FDA approved; PCAC recommended 503A Bulks List inclusion, FDA final determination pending |
Does Chia offer BPC-157 or TB-500?
Chia does not currently offer BPC-157 or TB-500. We are careful about this distinction because education about investigational peptides should not imply access, prescribing, or endorsement.
For treatments we do offer, Chia uses a 100% online model: a short health questionnaire, licensed US provider review, prescribing only where clinically appropriate, state-licensed 503A pharmacy compounding, and home delivery. Patients can message their care team through the portal. A prescription is never guaranteed, and compounded medications are not FDA-approved.
Our current longevity catalog includes sermorelin in injection, nasal spray, and tablet forms; GHK-Cu cream; glutathione injection or nasal spray; and NAD+ injection or nasal spray. We also offer the Foundation Longevity protocol, which combines sermorelin injection, NAD+ injection, and glutathione injection for patients who qualify.
| Chia treatment | Forms listed in Chia’s live catalog | Current starting price |
|---|---|---|
| Sermorelin | Injection, nasal spray, tablets | Injection and nasal spray plans currently start at $179/mo |
| GHK-Cu | Cream | Plans currently start at $159/mo |
| Glutathione | Injection, nasal spray | Plans currently start at $179/mo |
| NAD+ | Injection, nasal spray | Nasal spray plans currently start at $119/mo; injection plans currently start at $179/mo |
| Foundation Longevity | Sermorelin injection + NAD+ injection + glutathione injection | Plans currently start at $399/mo |
If you want help thinking through peptide goals without assuming BPC-157 or TB-500 is the answer, you can start with Chia’s online eligibility quiz. For treatments Chia offers, a licensed provider reviews your health history and decides whether any prescription is appropriate.
What should you ask a clinician before using recovery peptides?
Before using recovery peptides, the safest first step is to define the medical problem. A sore tendon, poor sleep, slow recovery, post-surgical pain, and an inflammatory condition may need very different care.
- 1What diagnosis or recovery goal is being treated?
- 2Are there approved therapies, rehabilitation plans, imaging tests, or lab checks with stronger evidence?
- 3How do my medications, anticoagulant use, immune history, heart history, pregnancy status, fertility plans, or cancer history change the risk?
- 4How would side effects be monitored, and what symptoms should trigger urgent care?
- 5Where would the product come from, and how are identity, strength, sterility, and contaminants tested?
- 6What is the plan if symptoms do not improve or get worse?
FAQ
Reported side effects include injection-site redness, pain, swelling, fatigue, headache, dizziness, nausea, appetite changes, and mood or sleep changes. True rates are not known because controlled human safety data are limited.
Reported TB-500 side effects are similar: injection-site irritation, fatigue, headache, dizziness, nausea, and nonspecific changes in appetite, mood, sleep, or energy. Direct human safety data for TB-500 are limited.
No. BPC-157 and TB-500 are not FDA-approved drugs for injury recovery, tissue repair, pain, longevity, or athletic performance. In July 2026, PCAC recommended both for 503A Bulks List inclusion, but that was advisory and FDA’s final determination is pending.
There is not enough human evidence to say BPC-157 is safe or unsafe for the heart. Because it is discussed in relation to nitric oxide and blood-vessel pathways, people with cardiovascular disease or symptoms like chest pain, fainting, palpitations, or shortness of breath should seek medical care.
There is no proof that BPC-157 or TB-500 causes cancer in humans. There is also no proof that they are safe for people with current or prior cancer. The concern is theoretical and relates to angiogenesis, inflammation, and tissue-remodeling pathways.
There is no FDA-approved daily dosing schedule for either peptide. Online cycle protocols are not medical guidance, and daily use should not be started without a licensed clinician reviewing the diagnosis, risks, and monitoring plan.
Oral products avoid injection-site and sterility risks, but they still raise questions about identity, strength, purity, absorption, dosing, and long-term safety. Oral does not automatically mean proven or risk-free.
No. Chia does not currently offer BPC-157 or TB-500. Chia offers only the treatments, forms, prices, and pages listed in its live catalog, with licensed-provider review and prescribing only when clinically appropriate.
References
- 1.Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal and Soft-Tissue Healing, 2025.
- 2.Emerging Use of BPC-157 in Orthopaedic Sports Medicine, 2025.
- 3.GlobalRPH. BPC-157 and TB-500: Background, Indications, Efficacy, Safety, and the Role of Cancer Pre-Screening in Clinical Use, 2025.
- 4.Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 1997.
- 5.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, 2026.
- 6.Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 1971.
- 7.Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta 4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 2005.
- 8.World Anti-Doping Agency. The 2026 Prohibited List: International Standard, 2026.
- 9.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials, July 23–24, 2026.
- 10.FDA Law Blog. FDA’s Pharmacy Compounding Advisory Committee Votes on Peptides Nominated for the 503A Bulks List, 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
